

HPV VACCINATION IN SANDYFORD SERVICES

What's New

From 1 April 2022 UK JCVI advice is to move to a **2-dose schedule at least 6 months apart** for everyone eligible aged 15 or over.

A **3-dose schedule** should be offered to those **known to be living with HIV** or who are **immunocompromised**

During 2022 Gardasil will be replaced by Gardasil-9

As these changes are yet to be fully implemented, national information leaflets and the Green Book may **not be consistent**

In Sandyford given pressure on clinic space **we will move immediately to the 2-dose schedule for those eligible.**

1. General information on HPV Vaccination
2. HPV vaccination in young people
3. HPV vaccination in MSM

1. General information

General Information for clinicians and clients

- HPV infections are spread primarily by sexual contact with an infected partner, affecting the skin and mucosa of respiratory and anogenital tracts
- The majority of HPV infections are asymptomatic and infection is usually cleared without the need for treatment. Persistent infection with high risk HPV types such as types 16 and 18 can lead to cancer – most notably cancer of the cervix, anus, throat and penis. HPV 6 and 11 cause 90% of all genital warts.

Vaccine-Information

- Gardasil® is the recommended vaccine and provides protection against four HPV strains: HPV-6,11,16,18
- Vaccine is made from virus-like particles (VLPs) that are not infectious and cannot cause HPV-associated cancers or genital warts as they do not contain the virus's DNA. VLPs are very immunogenic and induce high levels of antibody production by the body.
- Prior infection with one HPV type does not diminish the efficacy of the vaccine against other HPV types included in the vaccine.
- HPV vaccines have not been shown to have an impact on an existing infection but may boost immunity and prevent re-infection or reduce reoccurrences.

- The most common adverse reactions are injection-site reactions (77.1%). Others include headache, myalgia, fatigue, and low grade fever.
- Gardasil® is an inactivated vaccine and will not be affected by, nor interfere with other inactivated or live vaccines.

Contraindications

- Confirmed anaphylactic response to a previous dose or any component of the vaccine.
- Defer vaccination if recipient has fever or is acutely unwell.

Administration

- During storage a white precipitate may develop and the vaccines should be shaken before use to form a white milky cloud.
- Vaccines are given by intramuscular injection into deltoid muscle.
- Anaphylaxis is possible but extremely rare.

2. HPV Vaccination - Vulnerable young people**Background**

Since September 2019, the HPV vaccine has been offered to girls and boys in first year of secondary school as part of the routine school-based programme. This follows the Scottish Government announcement in July 2018 to include HPV vaccination to boys in the national vaccination programme on the advice of the Joint Committee of Vaccination and Immunisation (JCV). dosing schedule is 2 doses for those commencing a course under the age of 15 years old and 3 doses if over 15 years (changing during 2022 to 2-doses unless immunosuppressed).

Sandyford can provide vaccination to vulnerable young people identified at the time of consultation as being eligible to receive the vaccine but who are unable to access vaccine through the school program. An 'Unscheduled Form' should be completed for all these cases (see below).

Inclusion Criteria

- Vulnerable young people aged 12 to 25 years presenting to Sandyford services who are or have been excluded from school; or have never attended school and therefore have been unable to access the school vaccine program. Those in eligible cohorts for vaccination in the national programme will remain eligible, and may be offered HPV vaccination opportunistically, up to their 25th birthday.
- Note boys should only be included in this if they were born after 2008 and have missed the school vaccination programme

Exclusion criteria

- Females aged 25 years and over
- Boys born prior to 2008.
- Pregnancy (limited data)

Dosage & schedule

Gardasil 0.5ml IM on initial day of attendance and 6 months later (if under 15 years of age)

Second dose: the minimum time between the 1st and 2nd doses should be 6 months, and the 2nd dose should be given within 24 months of the 1st dose

If the course is interrupted, even if greater than 24 months, resume the course with the same vaccine. There is no need to repeat the course.

Women known to be living with HIV should have a 3-dose course due to lack of clinical evidence of efficacy in this group for the 2-dose schedule. This is: day of attendance, 1 month and 4 months

Record Keeping / Documentation

- Provide client with a Patient Information Leaflet and offer HPV vaccination
- If client declines vaccination, record on NaSH (see Appendix 1)
- If client accepts vaccination:
 - Prescribe and record on NaSH that vaccination commenced
 - Provide HPV vaccination card
 - Make appointments for subsequent vaccinations
 - Set up SMS recall for subsequent vaccinations in Special Forms - patient actions and recalls (see Appendix 2).

An 'Unscheduled Form' should be completed and returned to:
Screening Department, 1st Floor, Building 2, Templeton Business Centre, 62 Templeton Street, Glasgow, G40 1DA for every HPV vaccine administered.

Forms are available in Public Folders at <\\Fileserver3\public folders\01 Protocols, Policies and Guidelines\Guidelines>.

It is possible to confirm the vaccine status of any client presenting by contacting the School Health System Team during office hours:

Child Health Team for School
Templeton Business Centre
62 Templeton Street
Glasgow
G40 1DA

Tel. 0141 277 7642

3.HPV vaccination: MSM

From July 2017, the HPV vaccine has been offered opportunistically at Sandyford (central and hubs) to men who have sex with men (MSM) up to and including 45 years of age

Why MSM?

- In all men 80-85% of anal cancers, 30-70% of oro-pharyngeal cancer and 50% of penile cancers are associated with HPV infection.
- MSM bear a significantly increased burden of HPV related disease compared to heterosexual men. HPV type 16-associated anal cancers in particular are far more common in MSM.
- Men aged 46 and above are not offered HPV vaccination as research/review has shown the HPV vaccination to have a health benefit and be cost effective to MSM up to the age of 40 this has been extrapolated to the age of 45 but not beyond this.
- The current HPV vaccine programme for girls induces herd protection, which provides substantial protection to heterosexual boys and men.

What dose to use?

- For those without HIV or immunosuppression **just a two-dose course is needed** for protection with at least six months between doses
- Those who had interruptions to their course prior to April 2022 and have had two doses with at least six months between them do **not** require a third dose
- A course of **three injections** is needed for those living with HIV or who are immunosuppressed, or where the initial two doses were not at least six months apart. The second dose should be administered at least 1 month after initial dose and the third dose administered at least 4 months after the first dose, ideally completed within 12 months. If the vaccine course is interrupted, it should be resumed but not repeated.

Gardasil 0.5ml IM : on initial day of attendance and then again at least six months later

What to do when an MSM 45 years or under attends Sandyford

- Provide client with a Patient Information Leaflet and offer HPV vaccination
- If client declines vaccination, record on NaSH (see Appendix 1)
- If client accepts vaccination:
 - Prescribe and record on NaSH that vaccination commenced
 - provide HPV vaccination card
 - make 1 month appointment for second vaccination
 - set up SMS for 4 month recall for third vaccination in Special Forms - patient actions and recalls (see Appendix 2).

References

www.hps.scot.nhs.uk/immvax/hpv (accessed online March 2021)

www.gov.uk/government/publications/human-papillomavirus-hpv-the-green-book-chapter-18a (accessed online March 2022)

www.nhsinform.scot/healthy-living/immunisation/vaccines/hpv-vaccine-for-men-who-have-sex-with-men-msm (accessed online March 2022)

UKHSA NHS letter [Changing to a 2 dose NHS HPV vaccination schedule letter \(publishing.service.gov.uk\)](https://publishing.service.gov.uk)

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1056046/B1322_changing-to-a-2-dose-NHS-HPV-vaccination-schedule-for-eligible-adolescents-and-adults-starting-the-course-after-they-turn-15-years-old-including-men-who-have-sex-with-men-240222.pdf [England only, Scottish CMO letter still in draft] [accessed 08 Mar 2022]

Appendix 1. Recording of HPV Vaccination.

Appendix 2. SMS reminder – Patient Action and Recall